Image by Joshua Earle

PIONEER FUND

SWV ARE COMMISSIONING TRIALS OF MDMA-ASSISTED PSYCHOTHERAPY: A POTENTIAL BREAKTHROUGH IN PTSD TREATMENT

For too many UK veterans, the battle isn’t over when combat ends.

Nearly one in five UK combat veterans suffers from Post-Traumatic Stress Disorder or PTSD. And it’s been estimated that one third to one half of PTSD cases overall are resistant to treatment.

Their struggle with PTSD can be all-consuming and at times overwhelming.

But PTSD therapy is a challenge in itself – and for many veterans current therapies offer only a modest chance of success. Most therapies for PTSD require patients to relive the trauma over and over – and the painful emotions that involves limits the effectiveness of the treatment.  

Now, researchers have developed a new form of PTSD treatment – MDMA-assisted psychotherapy.  This potential breakthrough approach uses medical doses of MDMA to reduce the fear response and help patients access their innate capacity for resilience and for post-traumatic growth. MDMA enhances psychotherapy by enabling patients to better process the trauma with the aid of their psychotherapists.

Supporting Wounded Veterans is proud to join the worldwide research programme assessing what may well prove to be a remarkable treatment.  At the one year follow-up to Phase 2 Trials, 67 percent of study participants no longer qualified for a diagnosis of PTSD.

To find out more about PTSD and this highly promising new therapy, and to learn about the upcoming trial, click on the links below.

WHY MDMA-ASSISTED PSYCHOTHERAPY?

THE SCIENCE BEHIND MDMA-ASSISTED PSYCHOTHERAPY

FREQUENTLY ASKED QUESTIONS

SUPPORTING WOUNDED VETERANS’ MDMA-ASSISTED PSYCHOTHERAPY PROGRAMME

As part of their support for the programme Supporting Wounded Veterans are able to offer Veterans who volunteer the opportunity to explore the benefits of MDMA-assisted psychotherapy, and by doing so to contribute to research, by participating in a trial at King's College London

We are raising funds for 20 or more veterans to take part in the upcoming Phase 2 and 3 trials at King’s College London. The Phase 3 study planned to start in 2021 will be a substantial part of the application to the  European Medicines Agency.The EMA has agreed that it will accept data submitted for FDA approval for MDMA – anticipated in 2022 or early 2023 if results are positive – and require an additional 70 people go through the European trials.

 

We support this research because we hope it will be a game-changer in this complex and difficult field, and because it is fully consistent with our purpose - that we, together, can make a change and help veterans overcome the challenges they face.

GET IN TOUCH

We'd love to hear from you

Send us an Email

Give us a Call

  • White Facebook Icon

Find us on Facebook

The work and programmes of Supporting Wounded Veterans is funded entirely by donations, sponsorship and contributions. We sincerely appreciate any donation that you might be able to give and you can give in a number of ways, from sponsoring individuals, events, or projects as well as donations.

Supporting Wounded Veterans

The Garden House
​Royal Hospital Chelsea
Royal Hospital Road,
London. ​SW3 4SR

Company Details

Registered Charity

No. 1149727

Limited by Guarantee

Registered in England 

No. 08258649

© COPYRIGHT 2021. ALL RIGHTS RESERVED.